Abstract

Strong efficacy in a particularly sick patient population could help differentiate Exelixis' Phase III medullary thyroid cancer candidate cabozantinib from the only FDA-approved drug for this rare disease - AstraZeneca's Caprelsa, the company suggested during an Oct. 27 earnings call. Medullary thyroid cancer is a small market, with an estimated 1,300 to 2,200 new cases in the U.S. each year. Caprelsa (vandetanib) became the first drug to win FDA approval for the indication in April.For the cabozantinib...